These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 39070784)

  • 1. Comparing the adverse effects of ketamine and esketamine between genders using FAERS data.
    Yang X; Chen D
    Front Pharmacol; 2024; 15():1329436. PubMed ID: 39070784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).
    McIntyre RS; Mansur RB; Rosenblat JD; Teopiz KM; Kwan ATH
    Expert Opin Drug Saf; 2024 Jun; ():1-6. PubMed ID: 38884147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
    Kwan ATH; Rosenblat JD; Mansur RB; Teopiz KM; McIntyre RS
    J Affect Disord; 2024 Sep; 360():421-426. PubMed ID: 38795777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
    Gastaldon C; Raschi E; Kane JM; Barbui C; Schoretsanitis G
    Psychother Psychosom; 2021; 90(1):41-48. PubMed ID: 32854103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.
    Kwan ATH; Rosenblat JD; Mansur RB; Rhee TG; Teopiz K; Le GH; Wong S; Cao B; Ho R; McIntyre RS
    J Affect Disord; 2024 Oct; 363():589-594. PubMed ID: 39029700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study.
    Wang J; Huang J; Yang S; Cui C; Ye L; Wang SY; Yang GP; Pei Q
    Drug Des Devel Ther; 2019; 13():4135-4144. PubMed ID: 31827320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis.
    Rodolico A; Cutrufelli P; Di Francesco A; Aguglia A; Catania G; Concerto C; Cuomo A; Fagiolini A; Lanza G; Mineo L; Natale A; Rapisarda L; Petralia A; Signorelli MS; Aguglia E
    Front Psychiatry; 2024; 15():1325399. PubMed ID: 38362031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database.
    Jiang Y; Du Z; Shen Y; Zhou Q; Zhu H
    Eur Arch Psychiatry Clin Neurosci; 2023 Dec; ():. PubMed ID: 38103077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.
    Bahji A; Zarate CA; Vazquez GH
    Expert Opin Drug Saf; 2022 Jun; 21(6):853-866. PubMed ID: 35231204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.
    Witt K; Potts J; Hubers A; Grunebaum MF; Murrough JW; Loo C; Cipriani A; Hawton K
    Aust N Z J Psychiatry; 2020 Jan; 54(1):29-45. PubMed ID: 31729893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis.
    Chen CC; Zhou N; Hu N; Feng JG; Wang XB
    Neuropsychiatr Dis Treat; 2023; 19():587-599. PubMed ID: 36942150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
    Jiang A; Wei C; Zhu W; Wu F; Wu B
    Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
    CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of ketamine and esketamine in treatment of depression.
    Nikayin S; Murphy E; Krystal JH; Wilkinson ST
    Expert Opin Drug Saf; 2022 Jun; 21(6):777-787. PubMed ID: 35416105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
    Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
    Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
    Singh B; Vande Voort JL; Pazdernik VK; Frye MA; Kung S
    J Affect Disord; 2024 Apr; 351():534-540. PubMed ID: 38302067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 19. Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review.
    Jollant F; Colle R; Nguyen TML; Corruble E; Gardier AM; Walter M; Abbar M; Wagner G
    Ther Adv Psychopharmacol; 2023; 13():20451253231151327. PubMed ID: 36776623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.
    Zhou Y; Lan X; Wang C; Zhang F; Liu H; Fu L; Li W; Ye Y; Hu Z; Chao Z; Ning Y
    J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):507-518. PubMed ID: 37414272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.